These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Central nervous system-related safety and tolerability of add-on ketamine to standard of care treatment in treatment-resistant psychotic depression in patients with major depressive disorder and bipolar disorder. Gałuszko-Wȩgielnik M; Jakuszkowiak-Wojten K; Wiglusz MS; Cubała WJ; Pastuszak M Front Neurosci; 2023; 17():1214972. PubMed ID: 37496742 [TBL] [Abstract][Full Text] [Related]
3. Ketamine for psychotic depression: An overview of the glutamatergic system and ketamine's mechanisms associated with antidepressant and psychotomimetic effects. Le TT; Di Vincenzo JD; Teopiz KM; Lee Y; Cha DS; Lui LMW; Rodrigues NB; Ho RC; Cao B; Lin K; Nasri F; Gill H; Lipsitz O; Subramaniapillai M; Mansur RB; Rosenblat JD; McIntyre RS Psychiatry Res; 2021 Dec; 306():114231. PubMed ID: 34798487 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. Daly EJ; Trivedi MH; Janik A; Li H; Zhang Y; Li X; Lane R; Lim P; Duca AR; Hough D; Thase ME; Zajecka J; Winokur A; Divacka I; Fagiolini A; Cubala WJ; Bitter I; Blier P; Shelton RC; Molero P; Manji H; Drevets WC; Singh JB JAMA Psychiatry; 2019 Sep; 76(9):893-903. PubMed ID: 31166571 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201 [TBL] [Abstract][Full Text] [Related]
7. Esketamine for Unipolar Major Depression With Psychotic Features: A Retrospective Chart Review and Comparison With Nonpsychotic Depression. Souza-Marques B; Telles M; Leal GC; Faria-Guimarães D; Correia-Melo FS; Jesus-Nunes AP; Vieira F; Souza L; Lins-Silva D; Mello RP; Guerreiro-Costa L; Bandeira ID; Lacerda ALT; Sampaio AS; Quarantini LC J Clin Psychopharmacol; 2022 Jul-Aug 01; 42(4):408-412. PubMed ID: 35727083 [TBL] [Abstract][Full Text] [Related]
8. Case report: Intranasal esketamine for severe major depressive disorder with psychotic features. Carter M; Solsrud K; Mischel N Front Psychiatry; 2022; 13():937996. PubMed ID: 35958651 [TBL] [Abstract][Full Text] [Related]
10. Relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants. Singh JB; Fedgchin M; Daly EJ; Drevets WC Adv Pharmacol; 2020; 89():237-259. PubMed ID: 32616208 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and Tolerability of Two Novel "Standard of Care" Treatments-Intranasal Esketamine Versus Intravenous Ketamine-for Treatment-Resistant Depression in Naturalistic Clinical Practice: Protocol for a Pilot Observational Study. Gutierrez G; Rosenblat J; Hawken E; Swainson J; Vazquez G JMIR Res Protoc; 2022 May; 11(5):e34711. PubMed ID: 35604752 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). Fedgchin M; Trivedi M; Daly EJ; Melkote R; Lane R; Lim P; Vitagliano D; Blier P; Fava M; Liebowitz M; Ravindran A; Gaillard R; Ameele HVD; Preskorn S; Manji H; Hough D; Drevets WC; Singh JB Int J Neuropsychopharmacol; 2019 Oct; 22(10):616-630. PubMed ID: 31290965 [TBL] [Abstract][Full Text] [Related]
13. A systematic review of therapeutic ketamine use in children and adolescents with treatment-resistant mood disorders. Kim S; Rush BS; Rice TR Eur Child Adolesc Psychiatry; 2021 Oct; 30(10):1485-1501. PubMed ID: 32385697 [TBL] [Abstract][Full Text] [Related]
14. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. McIntyre RS; Rosenblat JD; Nemeroff CB; Sanacora G; Murrough JW; Berk M; Brietzke E; Dodd S; Gorwood P; Ho R; Iosifescu DV; Lopez Jaramillo C; Kasper S; Kratiuk K; Lee JG; Lee Y; Lui LMW; Mansur RB; Papakostas GI; Subramaniapillai M; Thase M; Vieta E; Young AH; Zarate CA; Stahl S Am J Psychiatry; 2021 May; 178(5):383-399. PubMed ID: 33726522 [TBL] [Abstract][Full Text] [Related]
15. Ketamine - Undrawn Lines between Medical and Recreational Use - Implications for Clinical Practice. Jonovska S; Sugnet T; Šendula-Jengić V Psychiatr Danub; 2021; 33(Suppl 4):1113-1117. PubMed ID: 35354177 [TBL] [Abstract][Full Text] [Related]
16. Esketamine for treatment resistant depression: a trick of smoke and mirrors? Gastaldon C; Papola D; Ostuzzi G; Barbui C Epidemiol Psychiatr Sci; 2019 Dec; 29():e79. PubMed ID: 31841104 [TBL] [Abstract][Full Text] [Related]